- 1 Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral
- 2

dynamics : implications to define correlates of protection against infection

- Guillaume Lingas¹, Delphine Planas^{2,3}, Hélène Péré^{4,5}, Darragh Duffy⁶, Isabelle Staropoli⁷,
 Françoise Porrot^{2,3}, Florence Guivel-Benhassine^{2,3}, Nicolas Chapuis⁸, Camille Gobeaux⁹,
 David Veyer^{4,5}, Constance Delaugerre^{10,11}, Jérôme Le Goff^{10,12}, Prunelle Getten¹³, Jérôme
 Hadjadj¹⁴, Adèle Bellino¹⁵, Béatrice Parfait¹⁶, Jean-Marc Treluyer¹⁷, Olivier Schwartz^{2,3},
 Jérémie Guedj^{1,‡}, Solen Kernéis^{1,18,#}, Benjamin Terrier^{19,20,#}
- 8 ¹ Université Paris Cité, IAME, INSERM, F-75018, Paris ;
- 9 ²Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
- 10 ³Vaccine Research Institute, Créteil, France.
- ⁴Microbiology Department, Virology Unit, APHP, Hôpital Européen Georges-Pompidou, F-75015, Paris, France
- 12 ⁵Université Paris Cité, INSERM UMRS1138 Functional Genomics of Solid Tumors laboratory, F-75006, Paris, France
- 13 ⁶Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France
- 14 ⁷Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
- 15 ⁸Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris,
- 16 France
- ⁹Department of automated biology, CHU de Cochin, AP-HP, Paris, France
- 18 ¹⁰Virology Department, AP-HP, Hôpital Saint-Louis, F-75010 Paris, France
- 19 ¹¹Université Paris Cité, Inserm U944, Biology of emerging viruses, F-75010, Paris, France
- 20 ¹²Université Paris Cité, Inserm U976, INSIGHT Team, F-75010, Paris, France
- 21 ¹³INSERM UMRS 970, Université Paris Descartes, Paris, France.
- 22 ¹⁴Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP.CUP,
- 23 Hôpital Cochin, Paris, France.
- 24 ¹⁵Unité de Recherche Clinique Cochin-Necker, AP-HP, Paris, France.
- 25 ¹⁶Fédération des Centres de Ressources Biologiques Plateformes de Ressources Biologiques AP-HP.Centre-Université Paris
- 26 Cité, Centre de Ressources Biologiques Cochin, Hôpital Cochin, F-75014, Paris, France
- 27 ¹⁷Unité de Recherche clinique, Hôpital Cochin, AP-HP.Centre Université de Paris, Paris, France.
- 28 ¹⁸Equipe de Prévention du Risque Infectieux (EPRI), AP-HP, Hôpital Bichat, F-75018 Paris, France
- ¹⁹Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP.CUP,
- 30 Hôpital Cochin, F-75014, Paris, France
- 31 ²⁰Université Paris Cité, INSERM U970, Paris Cardiovascular Research Center, F-75015, Paris, France.
- 32
- ³³ [#]These authors contributed equally to this work as co-senior authors.
- 34
 ‡Corresponding author: jeremie.guedj@inserm.fr

36 Abstract

37 Background

While anti-SARS-CoV-2 antibody kinetics have been well described in large populations of vaccinated individuals, we still poorly understand how they evolve during a natural infection and how this impacts viral clearance.

41 Methods

For that purpose, we analyzed the kinetics of both viral load and neutralizing antibody levelsin a prospective cohort of individuals during acute infection by Alpha variant.

44 <u>Results</u>

45 Using a mathematical model, we show that the progressive increase in neutralizing 46 antibodies leads to a shortening of the half-life of both infected cells and infectious viral 47 particles. We estimated that the neutralizing activity reached 90% of its maximal level within 48 8 days after symptoms onset and could reduce the half-life of both infected cells and 49 infectious virus by a 6-fold factor, thus playing a key role to achieve rapid viral clearance. 50 Using this model, we conducted a simulation study to predict in a more general context the 51 protection conferred by the existence of pre-existing neutralization, due to either vaccination 52 or prior infection. We predicted that a neutralizing activity, as measured by $ED_{50} > 10^3$, could 53 reduce by 50% the risk of having viral load detectable by standard PCR assays and by 99% 54 the risk of having viral load above the threshold of cultivable virus.

55 Conclusions

56 This threshold value for the neutralizing activity could be used to identify individuals with 57 poor protection against disease acquisition.

59 Introduction

60 The analysis of viral and immunological kinetics during severe acute respiratory 61 coronavirus 2 (SARS-CoV-2) infection has provided important insights on some patterns of 62 the virus, both at the individual (within-host) and population (between-host) levels. For 63 instance, we and others have found that SARS-CoV-2 peak viral load was close or even 64 coincided with the onset of symptoms, suggesting that identifying individuals before 65 symptoms onset was key to efficiently reduce transmission¹. Likewise, we and others 66 identified that dynamics of viral load after the peak was associated with the risk of severe 67 disease, and we used these predictions to quantify the clinical efficacy of antiviral 68 strategies^{1,2}. In addition, mathematical models of antibody kinetics after vaccination also 69 played a key role to identify correlates of protection against severe infection³.

70 A question that has remained largely unsolved is the impact of antibody kinetics on 71 viral clearance, and how the induction of antibodies modulates the time to viral clearance. 72 Because the virus constantly mutates, it has been shown in large observational studies that 73 the measurement of total anti-Spike (S) IgG antibodies was important⁴⁻⁶, but that their 74 neutralization capacity was also critical⁷. Neutralization titers (ED50; half-maximal effective 75 dilution), provides a much more accurate description of the quantitative and qualitative level 76 of protection of patients' sera, against the different Variants of Concerns (VoC) that emerged 77 since 2021. This approach has been extensively used to analyze the magnitude and the 78 duration of the protection conferred by mRNA vaccines⁸, and has played an important role to 79 support booster dose strategies, or alert on the low level of protection of mRNA vaccine against disease acquisition in the Omicron variant era^{9,10}. 80

However, the combined kinetic analysis of both viral dynamic and neutralizing activity has never been studied in detail in the context of an acute infection. Here, we relied on the AMBUCOV cohort, a cohort of ambulatory individuals that took place in 2021 during the Alpha variant wave in France, prior to the mass vaccination campaign. Individuals were 85 included early after symptoms onset, and both virological and immunological parameters 86 were followed prospectively. We provided a detailed picture of the kinetics of antibody 87 neutralization capacity against the Alpha variant, but also against the VoC that emerged 88 subsequently, including Delta and Omicron (BA.1) variants. Following previous studies in 89 hospitalized patients¹¹, we used mathematical modeling to characterize the impact of the 90 evolution of the neutralization activity on viral kinetics after a natural infection. Then we used 91 this model to predict how the presence of a pre-existing neutralization activity (such as 92 conferred by natural infection or vaccination) may reduce viral replication. We put these 93 results in perspective to discuss the efficacy of vaccines and more broadly the use of 94 neutralizing titers as a correlate of protection against disease acquisition.

95

96 Patients and methods

97 Study design

98 The AMBUCOV study (APHP201285, N° IDRCB /EUDRACT: 2020-A03102-37, 99 ClinicalTrial.gov: NCT04703114) is a non-interventional longitudinal study that included 63 100 individuals between 05 February 2021 and 20 May 2021 in Cochin Hospital (Paris, France). 101 The AMBUCOV study was an ancillary study of the cross-sectional SALICOV study 102 (NCT04578509), that aimed to compare diagnostic accuracy of two alternate diagnosis 103 strategies (nasopharyngeal antigen test and saliva nucleic acid amplification testing) to the 104 current reference standard (nasopharyngeal nucleic acid amplification testing) for detection 105 of SARS-CoV-2 in community testing centers¹². The SALICOV study was conducted in the 106 network of community screening centers of the Assistance Publique-Hôpitaux de Paris 107 (APHP), France. Briefly, all individuals with symptoms (i.e., temperature > 37.8 °C or chills, 108 cough, rhinorrhea, muscle pain, loss of smell or taste, unusual persistent headaches, or 109 severe asthenia) were invited to be tested for SARS-CoV-2 in two community screening 110 centers located in Paris. Testing was also available to all asymptomatic individuals wishing to be tested (i.e., contact of infected cases, before or after travel, after participation to a gathering event). Once their participation to SALICOV was completed, participants tested positive for SARS CoV-2 were contacted by phone by the principal investigator (BT) to explain the study protocol and offered to participate in the AMBUCOV study. Home visits were organized and written informed consent was obtained from all included participants (or their legal representatives if unable to consent).

Exclusion criteria included patients with criteria for hospitalization at the time of diagnosis, non-consent or inability to obtain consent, patients with dementia or not authorized, for psychiatric reasons or intellectual failure, to receive information on the protocol and to give informed consent, and patients under guardianship or curatorship.

121 Study population and procedures

All adults included in the SALICOV study, with a positive nasopharyngeal PCR for SARS-CoV-2 within 48 hours, either with or without symptoms were included in the AMBUCOV study.

For each participant, four home visits were done by study nurses on day 0 (defined as the first study visit), day 3, day 8 and day 15. Blood samples were collected at each home visit, saliva on day 3, day 8 and day 15, nasal swab on day 8 and day 15 and stools on day 3 and day 15.

A follow-up study was performed at Cochin Hospital (Paris, France) on day 90 to collect outcome data and additional biological samples (blood, saliva and stools). Saliva samples were self-collected under supervision of the nurse or the principal investigator. Blood samples, saliva and stools samples were centralized, frozen in several aliquots at-80°C

133 within 24 hours and stored for analysis.

134 Data collection

We collected data on sociodemographic, past medical history, presence of symptoms and concomitant medications using a standardized data collection form. When missing, date of symptom onset was imputed at the median observed in the population.

138 Role of the funding sources

The AMBUCOV study was supported by the Fonds IMMUNOV, for Innovation in Immunopathology. An additional grant was obtained for immunological and virological experiments (COVID-19 grant number COV21039). The funding sources had no role in the study's design, conduct, and reporting.

143 Institutional Review Board (IRB) approval

144 The IRB C.P.P. lle de France III approved the study protocol prior to data collection 145 (approval number Am8849-2-3853-RM) and all subsequent amendments.

146 Quantification of SARS-CoV2 RNA in saliva samples

147 Viral RNA was extracted from saliva samples using the Cellfree200 V7 DSP 200 protocol 148 with the QIAsymphony® DSP virus/pathogen mini kit (QIAGEN, UK). Samples loaded onto 149 the QIAsymphony® SP as instructed by the manufacturer, with a 200 µl sample input 150 volume and 60 µl elution output volume of AVE buffer, unless stated (QIAGEN, UK). SARS-151 CoV-2 RT-ddPCR assays were performed using the One-Step RT-ddPCR Advanced Kit for 152 90 Probes (Bio-Rad Laboratories, Hercules, CA, USA) and the QX200 ddPCR platform 153 (Biorad). A 2-plex RT-ddPCR assay was developed, which targets the Nucleocapside (N1) 154 gene of the SARS-CoV-2 positive-strand RNA genome with specific FAM- probe and primers 155 Cy5-labeled probe for the detection of a human housekeeping gene (RNAseP). RNAseP 156 positivity was necessary to validate the RT-PCR assay prior to any further analysis. We considered 6 log₁₀ copies/mL as a proxy for positive viral culture¹¹. 157

159 The S-Flow assay is based on the recognition of the SARS-CoV-2 spike protein expressed 160 on the surface of 293T cells. It was used to quantify SARS-CoV-2-specific IgG and IgA subtypes in sera as previously described^{13,14}. Briefly, 293T cells were obtained from ATCC 161 162 (ATCC Cat# CRL-3216, RRID:CVCL_0063) and tested negative for mycoplasma. 293T cells 163 stably expressing Spike (293T S) or control (293T Empty) were transferred into U-bottom 96-164 well plates (10⁵ cells/well). Cells were incubated at 4°C for 30 min with serum (1:300 165 dilution), saliva (1:5 dilution) or nasopharyngeal swabs (1:5 dilution) in PBS containing 0.5% 166 BSA and 2 mM EDTA. Then, cells were washed with PBS, and stained at 4°C for 30 min 167 using anti-IgG AlexaFluor647 (Jackson ImmunoResearch cat# 109-605-170) and Anti-IgA 168 AlexaFluor488 (Jackson ImmunoResearch cat# 109-545-011). Then, cells were washed with 169 PBS and fixed 10 min with 4% PFA. Data were acquired on an Attune Nxt instrument (Life 170 Technologies). Results were analyzed with FlowJo 10.7.1 (Becton Dickinson). The specific 171 binding was calculated as follow: 100 x (% binding 293T Spike - % binding 293T Empty)/ 172 (100 - % binding 293T Empty). For sera, the assay was standardized with WHO international 173 reference sera (20/136 and 20/130) and cross-validated with two commercially available 174 ELISA (Abbott and Beckmann) using a Passing-Bablok linear regression model to allow 175 calculation of BAU/mL¹⁵. SARS-CoV-2 neutralization was assessed using the S-fuse assay, 176 as previously described¹⁶.

177 S-Fuse neutralization assay

U2OS-ACE2 GFP1-10 or GFP 11 cells, also termed S-Fuse cells, become GFP+ when they are productively infected by SARS-CoV- 2^{17} . Cells tested negative for mycoplasma. Cells were mixed (ratio 1:1) and plated at 8×10^3 per well in a µClear 96-well plate (Greiner Bio-One). The indicated SARS-CoV-2 strains were incubated with serially diluted sera for 15 min at room temperature and added to S-Fuse cells. Sera were heat-inactivated for 30 min at 56 °C before use. 18 h later, cells were fixed with 2% PFA, washed and stained with Hoechst (dilution of 1:1,000, Invitrogen). Images were acquired using an Opera Phenix high-content confocal microscope (PerkinElmer). The GFP area and the number of nuclei were quantified
using the Harmony software (PerkinElmer). The percentage of neutralization was calculated
using the number of syncytia as value with the following formula: 100 × (1 –
(value with serum – value in 'non-infected')/(value in 'no serum' – value in 'non-infected')).
Neutralizing activity of each serum was expressed as the half maximal effective dilution

190 (ED50).

191 Viral strain

B.1.1.7 (Alpha variant) was isolated from an individual in Tours (France) who had returned
from the UK (PMID: 33772244). B.1.617.2 (Delta variant) was isolated from a
nasopharyngeal swab of a hospitalized patient who had returned from India. The swab was
provided and sequenced by the Laboratoire de Virologie of the Hôpital Européen Georges
Pompidou (Assistance Publique des Hôpitaux de Paris) (PMID: 34237773). The Omicron
BA.1 strain was supplied and sequenced by the NRC UZ/KU Leuven (Leuven, Belgium)
(PMID: 35016199).

All individuals provided informed consent for the use of the biological materials. The variant strains were isolated from nasal swabs on Vero cells and amplified by one or two passages on Vero cells.

Titration of viral stocks was performed on Vero E6, with a limiting dilution technique allowing a calculation of TCID50, or on S-Fuse cells. Viruses were sequenced directly on nasal swabs, and after one or two passages on Vero cells. Sequences were deposited in the GISAID database immediately after their generation, with the following IDs: Alpha: EPI ISL 735391; Delta: ID: EPI ISL 2029113; Omicron BA.1.

207 Model for antibody and ED₅₀ kinetics

We modeled the evolution of IgG levels using a sigmoid Gompertz function to reflect the progressive increase in IgG from 0 (before infection) to a plateau, noted IgG_{max}:

$$IgG(t) = IgG_{max} \times e^{-e^{(A-B\times t)}}$$

210 We next relate IgG to the evolution of the neutralizing activity (*ED*₅₀) against different strains,

211 namely Alpha (α), Delta (δ) and Omicron (BA.1, σ) using the following relationship:

$$ED_{50}^{\alpha}(t) = \zeta \times IgG(t)$$
$$ED_{50}^{\delta}(t) = f_{\delta} \times \zeta \times IgG(t)$$

212 $ED_{50}^{o}(t) = f_0 \times \zeta \times IgG(t),$

such that \Box represents the scaling factor between IgG and ED_{50}^{α} , while f_{\Box} (resp f_{\Box}) represent the fold change between the neutralization capacity against alpha and delta variant (resp. omicron). Of note, in this model, the time to reach 90% of the maximal protection is the same for all variants and is equal to (A - log(-log(0.9))/B).

217 Model for viral dynamics in saliva

218 We used a target-cell limited model with an eclipse phase as described before¹¹ 219 (Supplementary Figure 1) to characterize viral dynamics in saliva from infection (t=0) to 220 clearance. In brief, the model includes three types of cell populations: target cells (T), 221 infected cells in an eclipse phase (I_1) and productively infected cells (I_2) . The model assumes 222 that target cells are infected at a constant infection rate β (mL.virion⁻¹.d⁻¹). Once infected, 223 cells enter an eclipse phase and become productively infected after a mean time 1/k (day). 224 We assume that productively infected cells have a constant loss rate, noted δ (d⁻¹). Infected 225 cells produce p viral particles per day (virus.d⁻¹), but only a fraction of them, μ , is infectious, 226 and the virus particles can either be infectious (V₁) or non-infectious (V_{NI}). We assumed that 227 viral load, as measured by RNA copies (V), is the sum of infectious and non-infectious viral 228 particles, both cleared at the same rate, c. The model can be written as :

$$\frac{dT}{dt} = -\beta V_i T$$

$$\frac{dI_1}{dt} = \beta V_i \ T - kI_1$$

$$\frac{dI_2}{dt} = kI_1 - \delta I_2$$
(Eq. 1)
$$\frac{dV_i}{dt} = p\mu I_2 - cV_I$$
$$\frac{dV_{ni}}{dt} = p(1 - \mu) - cV_{NI}$$

The basic reproductive number R_0 , defined by the number of secondary infected cells resulting from one infected cell in a population of fully susceptible cells, T_0 , is defined by :

$$R_0 = \frac{\beta p T_0 \mu}{c \delta}$$

232 Combined immunovirological model

Finally, we aimed to characterize the impact of the neutralizing antibody level on viral load. For that purpose, we tested several models, assuming no effect of neutralization antibody levels (model M0, Eq. 1), or that the effect of neutralization could alternatively i) increase infected cell clearance (model M1), ii) increase the loss of both infectious and non-infectious virus (model M2), iii) or both (model M3) (**Supplementary Figure 1**).

238 Model M0:

239
$$\frac{dI_2}{dt} = kI_1 - \delta I_2, \frac{dV_I}{dt} = p\mu I_2 - cV_I, \frac{dV_{NI}}{dt} = p(1-\mu)I_2 - cV_{NI}$$

240 Model M1:

241
$$\frac{dI_2}{dt} = kI_1 - \delta[I_2 + \varphi_\delta \log 10(ED50_\alpha)], \frac{dV_I}{dt} = p\mu I_2 - cV_I, \frac{dV_{NI}}{dt} = p(1-\mu)I_2 - cV_{NI}$$

242 Model M2

243
$$\frac{dI_2}{dt} = kI_1 - \delta I_2, \frac{dV_I}{dt} = p\mu I_2 - c[V_I + \varphi_c \log 10(ED50_\alpha)], \frac{dV_{NI}}{dt} = p(1-\mu)I_2 - c[V_{NI} + \varphi_c \log 10(ED50_\alpha)]$$
244
$$\varphi_c \log 10(ED50_\alpha)]$$

245 Model M3:

246
$$\frac{dI_2}{dt} = kI_1 - \delta[I_2 + \varphi_\delta \log 10(ED50_\alpha)], \frac{dV_I}{dt} = p\mu I_2 - c[V_I + \varphi_c \log 10(ED50_\alpha)], \frac{dV_{NI}}{dt} = p(1 - 247 \mu)I_2 - c[V_{NI} + \varphi_c \log 10(ED50_\alpha)]$$

248 Assumptions on parameter values

249 We fixed c to 10 d⁻¹, k to 4 d⁻¹ and μ to 10⁻⁴ as previously published¹¹. As only the product

250 p×T₀ is identifiable, we also fixed the density of susceptible epithelial cells to the same value found in the upper respiratory tract, i.e., $T_0 = 1.33 \times 10^5$ cells.mL⁻¹. Further we assumed that 251 252 the duration of the incubation period was log-normally distributed, with a median value of 5 253 days a standard deviation of 0.125, such that 90% of individuals have an incubation period 254 between 3 and 7 days¹¹. Thus, only 3 viral parameters were estimated, namely p, δ and R₀, 255 along with their interindividual variabilities. Given the lack of data on the viral upslope, we 256 also fixed the standard deviation of the random effect associated to R_0 , denoted ω_{R0} to 0.5, as done previously¹⁸. 257

258 Inference & model selection

Models M0, M1, M2, and M1+M2 (i.e., a dual effects on both infected cells and virus clearance) were fitted to all data available, namely viral load, IgG and ED_{50} against all strains, assuming an additive error on the log-quantities. Parameters were estimated using non-linear mixed effect models and SAEM algorithm, using the same statistical methodology as previously described^{11,18,19}. Only the results obtained with the best model are presented.

264 Impact of a pre-existing neutralization capacity on viral dynamics

265 Next, we used the best model to anticipate the viral dynamics that could be observed in non-266 naive individuals, i.e., in individuals having a pre-existing neutralization due either natural 267 infection or vaccination. For that purpose, we assumed that one virus was present at t=0 268 (infection time), and we assumed different levels of neutralizing capacity ranging from 269 $ED_{50}=0$ to $ED_{50}=10^5$. For each value of ED_{50} we generated a large population of 5,000 270 virological profiles using the final immuno-virological model, and we calculated different viral 271 metrics. Of note, we made the conservative assumption here that the neutralizing capacity 272 remained constant during the infection, i.e., we did not consider any increase over time due 273 to stimulated immune response. As a sensitivity analysis, we also calculated the protection 274 obtained with the alternative models.

275 Materials availability statement

All codes, datasets for the modelling analysis and datasets for the figures, supplementary figures, tables and supplementary tables are available at https://datadryad.org/stash/share/oNDQyb2rNuSRXr8vjIZSHBtIIC6zp4h504gunxxjmbo.

279 **Conflict of interest**

280 CCG received study materials and payment or honoraria for lectures, presentations, 281 speakers bureaus, manuscript writing or educational events from Roche Diagnostics, 282 Nephrotek, Radiometer and Siemens Helthineers as well as study materials from 283 Hemcheck/Eurobio. CCG participated on a Data Safety Monitoring Board for Siemens 284 Helthineers and Gentian. CD received consulting fees from ViiV, Gilead and MSD. HP' 285 institution received grants or contracts from PHRC-K/INCA; ANRS; ARC Programme de 286 recherche clinique; CRC - APHP. HP received payment or honoraria for lectures, 287 presentations, speakers bureaus, manuscript writing or educational events from MSD; 288 Janssen ; ViiV and Seegene as well as support for attending meetings/travels from MSD and 289 Seegene. HP has patents planned, issued or pending (PCT/EP2021/064575 & 290 PCT/EP2021/065863). SK' institution received a grant from BioMérieux.

293

294 <u>Results</u>

295 Baseline characteristics

296 A total of 57 patients were included between February and September 2021 (Table 1). 297 Patients were mostly male (N=40, 63%), with a median age of 44 years (IQR: 35-57) and all 298 were infected with the Alpha variant. Fifty-five participants developed symptoms, and 2 299 remained asymptomatic throughout the study. Patients had very few comorbidities, and 300 hypertension (5%), chronic cardiac disease (5%), obesity (3%), and chronic kidney disease 301 (2%) were the most common comorbidities. One patient was fully vaccinated (2 doses) and 302 7 patients had received one dose of vaccination at the time of infection. The median time 303 between symptoms onset and inclusion in the AMBUCOV study was 4 (IQR: 3-6) days and 304 the median saliva viral load at inclusion was 6.27 (IQR: 5.61-6.93) log₁₀ copies/mL.

305 Immuno-virological modeling

306 All data used for the modeling exercise, namely viral load (in saliva), anti-S IgG and 307 neutralizing titers (in plasma or serum) are shown in **Figure 1** and **Supplementary Figure 2**.

The model best describing our data assumed that neutralizing antibodies acted on both infected cell and infectious virus clearance (M1+M2), and the model could well fit all data (**Figure 2**). Model parameters were in line with what we found in other studies^{1,18,19}, with a within-host R₀ equal to 22.6, a viral production rate of 4 x 10³ viruses/cell/day, and a loss rate of infected cells in absence of antibodies equal to $\delta = 0.26 d^{-1}$ (**Table 2**). The peak viral load occurred at symptom onset with a median level of 6.8 log₁₀ RNA copies/mL.

The population average maximal level of anti-S IgG after acute infection, IgG_{max} , was equal to 155 BAU/mL, corresponding to an antibody neutralization level against α variant, ζ^* 316 IgG_{max} , equal to 548 ED₅₀. After infection, antibodies rapidly increased, and we predicted that 317 90% of this maximal antibody protection was achieved as early as day 10 post-symptom 318 onset. This level of neutralization was achieved around day 6 after symptoms onset in 319 patients vaccinated with one dose, and the only patient that had received 2 doses at the time 320 of the infection reached this level only 4 days after symptoms onset, supporting that 321 vaccination considerably reduced the time to achieve high level of neutralization activity. At 322 antibody peak, we estimated that the half-lives of both infected cells and infectious virus 323 were shortened by respectively 6- and 7-fold (corresponding to loss rates for δ and c equals to 1.56 d⁻¹ and 77 d⁻¹, respectively). Because antibody levels reached their maximal value 324 325 after peak viral load, we did not find a significant association between the cumulated levels 326 of neutralizing antibody levels and viral load (Supplementary Figure 3). As all individuals 327 were infected with Alpha variant, the population average maximal level of neutralization 328 against Delta and BA.1 variants were much lower and were diminished by respectively 6.7-329 and 277.7-folds (ζ^* lgG_{max}*f_{Delta/Omicron}), leading to median ED₅₀ of 82 and 2, respectively, after 330 infection, reached around 19 days after symptom onset.

331 To address the impact of the temporal effect of antibody levels on viral clearance, we 332 simulated 5000 in silico virological profiles using the estimated parameter distributions and 333 considering that antibody could have either the two mechanisms of action (as found in our 334 model), only one of them or none of them (thus fixing alternatively φ_{δ} and/or φ_{c} to 0 in the 335 model). When considering the full model, the predicted median time to clearance after 336 symptoms onset was equal to 12 days, as compared to >50 in a model in which antibodies 337 had no effect (φ_{δ} = φ_{c} = 0). We observed that the effectiveness of IgG was predominantly 338 driven by its action on the loss rate of infected cells, with a median time to viral clearance 339 equal to 14 days when only the effects on infected cell was assumed ($\varphi_c = 0$) as compared 340 to >50 days when only the effects on infected viral particles was assumed ($\varphi_{\delta} = 0$) 341 (Supplementary Figure 4). Consistent with this prediction, the post-hoc analysis showed 342 that the early appearance of detectable neutralizing antibodies was associated with lower

viral levels at day 4 post-symptom onset, which corresponds to the median time of inclusion
in the study (r=0.47, (P<10⁻³, Supplementary Figure 3).

345

346

347

Impact of a pre-existing neutralization capacity on viral dynamics

348 Next, we used the model to anticipate the viral dynamics that could be observed in non-349 naive individuals after an encounter with the virus, i.e., in individuals having a pre-existing 350 neutralization due either natural infection or vaccination. For that purpose, we assumed that 351 infection is initiated at t=0 with only one infectious particle, and we assumed different levels 352 of neutralizing capacity ranging from $ED_{50}=1$ to $ED_{50}=10^5$ (see methods). This corresponds to 353 a within-host R₀ ranging from 22.5 (i.e., the value estimated in our population before 354 antibody secretion) to about 0.5. Using the model parameters, we simulated viral dynamics 355 of 5,000 individuals with each potential level of ED_{50} and we computed the following metrics: 356 peak viral load, probability of having detectable viral load at peak, probability of having viral 357 load > 6 \log_{10} copies/mL. The simulations showed that ED₅₀>1000 would be sufficient to 358 maintain 45% of individuals with viral load below the limit of detection at all times, and only 359 1% being at risk of transmitting the infection (i.e.peak viral load above > $6 \log_{10} \text{ copies/mL}$).

360 Discussion

361 In this work, we combined the kinetic analysis of saliva viral load and immune 362 response during an acute Covid-19, from infection to viral clearance in ambulatory patients 363 with non severe disease. We show that neutralizing antibodies on infected cells and, to 364 some extent, on circulating viral particles, played a key role to achieve viral clearance. The 365 neutralizing activity was largely variant-dependent, and ED_{50} was estimated to be equal to 366 548 against Alpha variant but decreased by 7- and 300-fold against Delta and Omicron BA.1 367 variants, respectively. We next performed simulations to predict the level of protection 368 against infection conferred by various pre-existing levels of antibody neutralization, and predicted that a level of $ED_{50} > 10^3$ was sufficient to prevent 50% of infections from being 369 370 detectable and 99% from being above the threshold of viral culture, used as a proxy of 371 infectiousness.

The AMBUCOV study population included patients with mild COVID-19 during the Alpha variant wave in France, prior to the mass vaccination campaign, to describe the natural course of viral load and immune response in immunocompetent patients without any strong comorbidities, as illustrated by patients characteristics. The decision was directly related to our main objective, i.e. to analyze the relationship between the virus and the immune response.

378 We have modeled the kinetics of both saliva viral load and immune response, mainly 379 the humoral response, during an acute COVID-19. We showed that the increase in 380 neutralizing antibodies leads to a shortening of the half-life of both infected cells and 381 infectious viral particles. We estimated that the neutralizing activity reached 90% of its 382 maximal level within 8 days after symptoms onset and could reduce the half-life of both 383 infected cells and infectious virus by a 6-fold factor, thus playing a key role to achieve rapid 384 viral clearance. To establish a correlate of protection against SARS-CoV-2 infection, we predicted that a neutralizing activity defined by $ED_{50} > 10^3$ could reduce by 50% the risk of 385

having viral load detectable in saliva by ultrasensitive ddPCR assays and by 99% the risk of having viral load above the threshold of cultivable virus. Overall, this value of neutralizing activity could be used to identify individuals with poor protection against disease acquisition.

Based on the data from a previous study⁸, we compared the level of neutralizing antibodies 389 390 in individuals hospitalized in a nursing home prior to an outbreak, and compared the levels 391 between individuals that experienced a breakthrough infection and those that remained 392 uninfected. While all individuals in this study were vaccinated, the median ED_{50} before 393 infection was 1429 in individuals that subsequently experienced a breakthrough infection 394 (with Omicron BA.1 variant) as compared to 2528 in those who did not. Similarly, in two 395 studies, levels of neutralizing antibodies were lower 1770 against Alpha and BA.5 variants 396 just before the respective breakthrough infection^{20,21}. These data during the Omicron wave support our findings and the threshold of neutralizing activity $ED_{50} > 10^3$ as a potential 397 398 correlate of protection against SARS-CoV-2 infection regardless of the variants.

399 Finally, our study has some limitations. Viral loads and IgG were not quantified from 400 same site, the first being obtained in saliva and the second in serum. Unfortunately the 401 neutralizing assay was not adapted to measure the neutralizing activity in saliva. Further, as frequently observed in acute infection^{1,18}, very few data could be measured before peak viral 402 403 load, which may cause a bias in the estimation of R_0 and, accordingly, their effects on loss 404 rates parameters. Finally, our identifiability analysis showed that the effect neutralization of 405 circulating viral particles φ_c was poorly identifiable (RSEE = 76%) and that the effect of 406 neutralization on infected cells clearance rate was barely identifiable as well (RSEE = 49%). 407 All identifiability metrics are available in Supplementary Table 4. As a consequence, we 408 conducted the same 5000 individual simulations as previously, this time using the estimates 409 of model M1, where only an effect on the clearance rate of infected cells was considered. In these simulations, we observed that above 10³ ED50, the resulting protection conferred did 410 411 not improve (Supplementary table 5), with peak viral loads and proportion of detectable 412 individuals at peak viral load being >98% at all concentrations.

In conclusion, our data show that $ED_{50} > 10^3$ could be a clinically relevant threshold value for the neutralizing activity to identify individuals with poor protection against disease acquisition. The evaluation of this threshold on larger cohorts is now warranted to evaluate whether it could be used to define a correlate of protection against disease acquisition.

417

418 References

- 419 1. Néant, N. et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in
- 420 hospitalized patients from the French COVID cohort. *Proc. Natl. Acad. Sci.* **118**,
- 421 e2017962118 (2021).
- 422 2. Ke, R., Zitzmann, C., Ho, D. D., Ribeiro, R. M. & Perelson, A. S. In vivo kinetics of
 423 SARS-CoV-2 infection and its relationship with a person's infectiousness. *Proc. Natl.*424 *Acad. Sci.* **118**, (2021).
- 425 3. Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune
- 426 protection from symptomatic SARS-CoV-2 infection. *Nat. Med.* 27, 1205–1211 (2021).
- 427 4. Chivu-Economescu, M. et al. Assessment of the Humoral Immune Response Following
- 428 COVID-19 Vaccination in Healthcare Workers: A One Year Longitudinal Study.
- 429 *Biomedicines* **10**, 1526 (2022).
- 430 5. Di Chiara, C. *et al.* Long-term Immune Response to SARS-CoV-2 Infection Among
- 431 Children and Adults After Mild Infection. *JAMA Netw. Open* **5**, e2221616 (2022).
- 432 6. Lo Sasso, B. *et al.* Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies
- 433 before and after the third dose of the BNT162b2 vaccine. Sci. Rep. 12, 8679 (2022).
- 434 7. Planas, D. *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody
- 435 neutralization. *Nature* **602**, 671–675 (2022).
- 436 8. Bruel, T. *et al.* Neutralising antibody responses to SARS-CoV-2 omicron among elderly
- 437 nursing home residents following a booster dose of BNT162b2 vaccine: A community-
- 438 based, prospective, longitudinal cohort study. *eClinicalMedicine* **51**, 101576 (2022).

- 439 9. Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and
- 440 BA.2 in patients receiving monoclonal antibodies. *Nat. Med.* 28, 1297–1302 (2022).
- 441 10. Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody
- 442 neutralization. *Nature* **602**, 671–675 (2022).
- 443 11. Néant, N. et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in
- 444 hospitalized patients from the French COVID cohort. Proc. Natl. Acad. Sci. U. S. A. 118,
- 445 e2017962118 (2021).
- 446 12. Kernéis, S. et al. Accuracy of saliva and nasopharyngeal sampling for detection of
- 447 SARS-CoV-2 in community screening: a multicentric cohort study. *Eur. J. Clin. Microbiol.*
- 448 Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 40, 2379–2388 (2021).
- 449 13. Grzelak, L. et al. Sex Differences in the Evolution of Neutralizing Antibodies to Severe
- 450 Acute Respiratory Syndrome Coronavirus 2. J. Infect. Dis. 224, 983–988 (2021).
- 451 14. Grzelak, L. et al. A comparison of four serological assays for detecting anti-SARS-CoV-2
- 452 antibodies in human serum samples from different populations. *Sci. Transl. Med.* **12**,
- 453 eabc3103 (2020).
- 454 15. Hadjadj, J. et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta
- 455 variants in immunocompromised patients with systemic inflammatory diseases. *Ann.*
- 456 *Rheum. Dis.* **81**, 720–728 (2022).
- 457 16. Planas, D. *et al.* Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to
 458 neutralizing antibodies. *Nat. Med.* 27, 917–924 (2021).
- 459 17. Buchrieser, J. *et al.* Syncytia formation by SARS-CoV-2-infected cells. *EMBO J.* 39,
 460 e106267 (2020).
- 461 18. Lingas, G. et al. Effect of remdesivir on viral dynamics in COVID-19 hospitalized
- 462 patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy
- 463 trial. J. Antimicrob. Chemother. (2022) doi:10.1093/jac/dkac048.
- 464 19. Gonçalves, A. et al. Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-
- 465 CoV-2 Viral Load. CPT Pharmacomet. Syst. Pharmacol. 9, 509–514 (2020).
- 466 20. Boudhabhay, I. et al. COVID-19 outbreak in vaccinated patients from a haemodialysis

- 467 unit: antibody titres as a marker of protection from infection. *Nephrol. Dial. Transplant.*
- 68 **37**, 1357–1365 (2022).
- 469 21. Planas, D. et al. Duration of BA.5 neutralization in sera and nasal swabs from SARS-
- 470 CoV-2 vaccinated individuals, with or without omicron breakthrough infection. *Med*
- 471 S2666634022004111 (2022) doi:10.1016/j.medj.2022.09.010.



Figure 1. Virological and immunological data analyzed in the AMBUCOV cohort. A. Saliva viral load. B. Serum concentration of IgG (BAU/mL). C-E. Neutralization activity of IgG against strains C. Alpha D. Delta. E. Omicron (BA.1). All data expressed in time since symptom onset. Triangles represent data below LOQ.



489

Figure 2. Median predictions of viral (A) and serological (B) kinetics. Circles are the
observed data and lines represent the simulation-based median predictions of the model.
Triangles represent data below LOQ. Darkblue: Viral load. Lightblue: IgG. Brown: ED₅₀α.
Pink: ED₅₀δ. Yellow: ED₅₀ο



Figure 3. Prediction of peak viral load distribution depending on ED₅₀ levels at
initiation of infection. Values of ED₅₀ : Pink: 0 ; Yellow: 10 ; Green: 100 ; Blue : 1000 ;
Purple : 10000 ; Red : 100000

	Median/N (IQR/%)
Age (years)	43 (33-54)
BMI (kg/m²)	23.9 (21.3-25.3)
Male Gender	36 (63%)
At least 1 comorbidity*	6 (11%)
Delay between symptom onset and inclusion	4 (3-6)
Vaccinated (1 dose)	7 (12%)
Vaccinated (2 doses)	1 (2%)
IgG (log₁₀ BAU/mL of serum)	0.5 (3-1.2)
Saliva viral load (log₁₀ copies/mL)	6.4 (5.74-6.93)
$\log_{10} ED_{50}^{\alpha}$	2.6 (2.1-3.5)
$\log_{10} ED_{50}^{\delta}$	2.1 (1.2-2.6)
Log ₁₀ <i>ED</i> ₅₀ ⁰	LOQ

500 *Hypertension, Obesity, Heart failure or Kidney failure

501

502 Table 1. Clinical and biological characteristics at inclusion in the AMBUCOV study.

498

Antibody neutralization level at infection (ED₅₀)	Median peak viral load (log ₁₀ copies/mL)	Probability of peak viral load above the limit of detection	Probability of peak viral load above the threshold of infectivity
0	7.2	100%	86%
10 ¹	6.0	99%	48%
10 ²	4.1	80%	12%
10 ³	1.9	55%	1%
10⁴	1.7	44%	0%
10 ⁵	1.6	38%	0%

Table 2. Predicted impact of a pre-existing antibody neutralization on viral kinetics.
 The limit of detection and the threshold of infectivity were set to 1.84 and 6 log₁₀
 copies/mL, respectively.

510 Supplementary figure 1. Viro-immunological model.





512 Supplementary figure 2. Individual fits of the whole population studied.







Supplementary figure 3. Correlations between predicted viral load 4 days post symptom onset and time to ED_{50} positivity (left) and AUCs of viral load and ED_{50} between 4 and 18 days after symptom onset.



Supplementary figure 4. Sensitivity analysis of each mode of action of neutralization. 521 Green: median predicted viral load of model M1+M2. Yellow: Clearance rate of viral particles 522 not increased by neutralization. Red: Clearance rate of infected cells not increased by 523 neutralization.





537 Supplementary Figure 5. Prediction of peak viral load distribution depending on ED_{50}

538 levels at initiation of infection using parameter estimates of model M1.

539540 Supplementary table 1. Parameter estimates of model M0.541

	Fixed effect	Random effect SD
R0	19.1 (58.3)	0.5
k (d ⁻¹)	4	-
p (virus/cell/d)	17704 (68.8)	1.76 (46.7)
c (d ⁻¹)	10	-
μ	0.0001	-
δ (d ⁻¹)	0.88 (7.32)	0.28 (24.6)
IgG _{max}	161 (15)	0.94 (12.0)
A	4.63 (11.4)	0.15 (50.9)
В	0.36 (13.8)	0.19 (46.7)
ζ	3.58 (21)	1.36 (12.3)
f _{delta}	0.15 (22.5)	1.26 (17.2)
fo	0.0037 (50.6)	1.11 (42.8)
Φδ	0	-
φ _c	0	-
BIC	1173.09	

Parameter estimate (RSE, %)

544545 Supplementary table 2. Parameter estimates of model M1.546

	Fixed effect	Random effect SD
R0	17.7 (58.3)	0.5
k (d ⁻¹)	4	-
p (virus/cell/d)	1803 (68.2)	2.23 (33.5)
c (d ⁻¹)	10	-
μ	0.0001	-
δ (d ⁻¹)	0.35 (21.6)	0.45 (28.9)
IgG _{max}	153.07 (14.7)	12.5 (12)
А	5.1 (8.58)	0.19 (69.3)
В	0.41 (9.86)	0.12 (198)
ζ	3.58 (20.1)	1.35 (12.2)
f _{delta}	0.15 (23.2)	1.32 (18.2)
f _o	0.0031 (109)	1.27 (88.2)
Φδ	1.14 (10.8)	-
Φc	0	-
BIC	1158.54	

Parameter estimate (RSE, %)

549 Supplementary table 3. Parameter estimates of model M2.550

	Fixed effect	Random effect SD
R0	17.9 (100)	0.5
k (d⁻¹)	4	-
p (virus/cell/d)	15609 (72.1)	2.03 (27.2)
C (d⁻¹)	10	-
μ	0.0001	-
δ (d⁻¹)	0.88 (7.77)	0.69 (16.8)
IgG _{max}	157.84 (14.7)	0.92 (12)
A	4.82 (9.56)	0.13 (46)
В	0.38 (11.6)	0.2 (31.2)
ζ	3.58 (21.2)	1.37 (12.4)
f _{delta}	0.15 (23.0)	1.3 (17.0)
fo	0.0024 (85.5)	1.5 (53.8)
Φ_{δ}	0	-
фс	<10 ⁻⁵ (>10 ³)	-
BIC	1176.88	

Parameter estimate (RSE, %)

Fixed effect Random effect SD R0 22.57 (33.5) 0.5 k (d⁻¹) 4 p (virus/cell/d) 4275.38 (63.2) 2.03 (27.2) c (d⁻¹) 10 -0.0001 μ δ (d⁻¹) 0.26 (14.7) 0.69 (16.8) **IgG**_{max} 155 (14.5) 0.94 (12) А 5.24 (11.3) 0.12 (52) В 0.42 (14.2) 0.21 (29.5) ζ 3.54 (20.9) 1.34 (12.5) 0.15 (22.7) 1.27 (16.7) **f**delta 0.0036 (81.6) 1.22 (63.7) fo 1.51 (3.90) Φδ -1.81 (2.47) фc -BIC 1159.27

Parameter estimate (RSE, %)

Supplementary table 5. Identifiability metrics of model M1+M2.

	Parameter estimate (RSE, %)	Empirical SE	Empirical RSE	RBias
R0	22.57 (33.5)	14.8	65	25
p (virus/cell/d)	4275.38 (63.2)	4971	116	41
δ (d ⁻¹)	0.26 (14.7)	0.08	30	-8.2
lgG _{max}	155 (14.5)	23	15	-2.6
A	5.24 (11.3)	0.6	11	2.3
В	0.42 (14.2)	0.06	13.6	3.3
ζ	3.54 (20.9)	0.77	22	5.1
f _{delta}	0.15 (22.7)	0.04	26	5.1
f _o	0.0036 (81.6)	0.0018	50.0	8.4
Φ_{δ}	1.81 (3.90)	0.75	50	23.5
фс	1.51 (2.47)	1.37	76	23.1

Supplementary table 6. Predicted impact of a pre-existing antibody neutralization on viral kinetics using model M1.

564

Antibody neutralization level at infection (ED ₅₀)	Median peak viral load (log ₁₀ copies/mL)	Probability of peak viral load above the limit of detection	Probability of peak viral load above the threshold of infectivity
0	6.6	100.0%	73%
10 ¹	6.4	100.0%	66%
10 ²	6.2	99.9%	59%
10 ³	6.1	99.9%	54%
10 ⁴	5.9	99.2%	46%
10 ⁵	5.7	98.6%	41%